N-methyl-D-aspartate antagonists: ready for clinical trial in brain ischemia?

Ann Neurol. 1989 Apr;25(4):398-403. doi: 10.1002/ana.410250412.

Abstract

Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well-developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK-801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.

Publication types

  • Clinical Trial
  • Review

MeSH terms

  • Aspartic Acid / analogs & derivatives*
  • Aspartic Acid / antagonists & inhibitors
  • Brain / drug effects
  • Brain / pathology
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology
  • Clinical Trials as Topic
  • Excitatory Amino Acid Antagonists
  • Glutamates / physiology
  • Glutamic Acid
  • Humans
  • Models, Neurological
  • N-Methylaspartate
  • Receptors, N-Methyl-D-Aspartate
  • Receptors, Neurotransmitter / drug effects
  • Receptors, Neurotransmitter / physiology
  • Synapses / physiology
  • Synaptic Transmission / drug effects

Substances

  • Excitatory Amino Acid Antagonists
  • Glutamates
  • Receptors, N-Methyl-D-Aspartate
  • Receptors, Neurotransmitter
  • Aspartic Acid
  • Glutamic Acid
  • N-Methylaspartate